VYLOY

This brand name is authorized in Austria, Estonia, Lithuania, United Kingdom, United States

Active ingredients

The drug VYLOY contains one active pharmaceutical ingredient (API):

1 Zolbetuximab UNII TF5MPQ8WGY - ZOLBETUXIMAB

Zolbetuximab is a chimeric (mouse/human IgG1) monoclonal antibody directed against the tight junction molecule CLDN18.2. Nonclinical data suggest zolbetuximab binds selectively to cell lines transfected with CLDN18.2 or those that endogenously express CLDN18.2. Zolbetuximab depletes CLDN18.2-positive cells via antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Read about Zolbetuximab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
VYLOY Powder for concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FX31		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX31

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3090260, 3090271
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1101286, 1101287
Country: US	FDA, National Drug Code	Identifier(s): 0469-3425